Here's What Key Metrics Tell Us About Amphastar (AMPH) Q3 Earnings

Core Insights - Amphastar Pharmaceuticals reported revenue of $191.21 million for the quarter ended September 2024, reflecting a 5.9$0.96, down from $1.15 in the same quarter last year, with an EPS surprise of -4.95$1.01 [1] Revenue Performance by Product - Primatene MIST generated net revenues of $26.06 million, exceeding the average estimate of$23.98 million, marking a year-over-year increase of 4.9% [3] - Epinephrine revenues were reported at $21.34 million, below the average estimate of$27.30 million, with a year-over-year increase of 5.7% [3] - Lidocaine revenues reached $15.88 million, surpassing the average estimate of$13.62 million, reflecting a 2.3% year-over-year increase [3] - Phytonadione revenues were $11.72 million, significantly above the average estimate of$9.43 million, showing a remarkable year-over-year increase of 57.4% [3] - API (Active pharmaceutical ingredients) revenues were reported at $1.46 million, falling short of the average estimate of$2.89 million, with a substantial year-over-year decline of 65.1% [3] - Enoxaparin revenues were $5.62 million, slightly below the average estimate of$6.08 million, representing a year-over-year decrease of 27.1% [3] - Naloxone revenues were $4.04 million, exceeding the average estimate of$3.83 million, but showing a year-over-year decline of 14.4% [3] - Total finished pharmaceutical products net revenues were $187.36 million, below the average estimate of$192.57 million, with a year-over-year increase of 26.9% [3] - Glucagon revenues were reported at $26.79 million, slightly above the average estimate of$26.65 million, reflecting a year-over-year decrease of 9.2% [3] Stock Performance - Amphastar's shares have returned +11.4% over the past month, outperforming the Zacks S&P 500 composite, which saw a +0.7% change [4] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market in the near term [4]